

09/607156

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Marcel Loetscher and Bernhard Moser

Patent No.: 6,833,439 B1

Issued: December 21, 2004

Title: IP-10/MIG RECEPTOR DESIGNATED CXCR3, NUCLEIC ACIDS, AND
METHODS OF USE THEREFOR

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
on <u>1-19-05</u>	<u>Sandra Jammal</u>
Date	Signature
<u>Sandra Jammal</u>	
Typed or printed name of person signing certificate	

Certificate
JAN 27 2005
of Correction

REQUEST FOR EXPEDITED ISSUANCE OF CERTIFICATE OF CORRECTION

Office of Publications
Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 35 U.S.C. § 254, we hereby request issuance of a Certificate of Correction for the above-referenced U.S. Patent. This request is made under 37 C.F.R. § 1.322, and is accompanied by evidence to show that the errors are attributable solely to the Office and by a completed Form PTO-1050 (1 sheet, with copy). Accordingly, expedited issuance of a Certificate of Correction is respectfully requested (M.P.E.P. § 1480.01).

The requested corrections are listed below.

JAN 31 2005

Column 45

Line 23, delete "1" and insert --7--.

Copies of pages 1-3 of the Amendment filed on May 26, 2004, with hand-written notations regarding renumbering of the claims and dependencies, and pointing out the position of the error, are transmitted in support of the requested correction.

Since the error was made by the U.S. Patent and Trademark Office, it is understood that there are no additional fees for the requested Certificate of Correction.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By *Helen E. Wendler*

Helen E. Wendler

Registration No. 37,964

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

Jan 19, 2005

JAN 31 2005

COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marcel Loetscher and Bernhard Moser

Application No.: 09/607,156

Group: 1646

Filed: June 29, 2000

Examiner: Janet L. Andres, Ph.D.

Confirmation No.: 8374

For: IP-10/MIG RECEPTOR DESIGNATED CXCR3, NUCLEIC ACIDS, AND
METHODS OF USE THEREFOR

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
<u>May 24 2004</u> Date	<u>Shannon Luis</u> Signature
<u>Shannon Luis</u> Typed or printed name of person signing certificate	

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Amendment is being filed in response to the Office Action mailed from the U.S. Patent and Trademark Office on February 25, 2004 in the above-identified application. Reconsideration and further examination are requested.

Please amend the application as follows:

JAN 31 2005

Amendments to the Claims

Please cancel Claims 16, 17, 61, 62, 65-68, 77-80, 85 and 86. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1.-18. (Canceled)

1 ~~19.~~ (Previously Presented) An isolated human CXC Chemokine Receptor 3 (CXCR3) protein encoded by the nucleic acid illustrated in Figure 1 (SEQ ID NO:1).

2 ~~20.~~ (Previously Presented) An isolated human CXC Chemokine Receptor 3 (CXCR3) protein comprising an amino acid sequence as set forth in Figure 2 (SEQ ID NO:2).

3 ~~21.~~ (Previously Presented) A fusion protein comprising a human CXC Chemokine Receptor 3 (CXCR3) protein, wherein the amino acid sequence of said CXCR3 protein is a sequence encoded by the nucleic acid illustrated in Figure 1 (SEQ ID NO:1).


22.-59. (Canceled)

4 ~~60.~~ (Previously Presented) A fusion protein comprising a human CXC Chemokine Receptor 3 (CXCR3) protein wherein the amino acid sequence of said CXCR3 protein consists of the amino acid sequence of Figure 2 (SEQ ID NO:2).

61.-62. (Canceled)

5 ~~63.~~ (Previously Presented) An isolated human CXC Chemokine Receptor 3 (CXCR3) protein or functional variant thereof, wherein the amino acid sequence of said CXCR3 protein or functional variant is at least about 90% identical to that of the protein shown in Figure 2 (SEQ ID NO:2), said CXCR3 protein or functional variant comprises the extracellular N-

terminal segment of the protein shown in Figure 2 (SEQ ID NO:2), and said CXCR3 protein or functional variant binds one or more chemokines selected from the group consisting of IP-10 and Mig.

- 6 ~~64~~. (Previously Presented) A fusion protein comprising a human CXC Chemokine Receptor 3 (CXCR3) protein or functional variant thereof, wherein the amino acid sequence of said CXCR3 protein or functional variant is at least about 90% identical to that of the protein shown in Figure 2 (SEQ ID NO:2), said CXCR3 protein or functional variant comprises the extracellular N-terminal segment of the protein shown in Figure 2 (SEQ ID NO:2), and said CXCR3 protein or functional variant binds one or more chemokines selected from the group consisting of IP-10 and Mig.
- 65.-68. (Canceled)
- 7 ~~69~~. (Previously Presented) The isolated human CXCR3 protein of Claim ~~19~~¹, wherein said protein is labeled with a detectable label.
- 8 ~~70~~. (Previously Presented) The isolated human CXCR3 protein of Claim ~~69~~⁷, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label. 
- 9 ~~71~~. (Previously Presented) The isolated human CXCR3 protein of Claim ~~20~~², wherein said protein is labeled with a detectable label.
- 10 ~~72~~. (Previously Presented) The isolated human CXCR3 protein of Claim ~~71~~⁹, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label.
- 11 ~~73~~. (Previously Presented) The fusion protein of Claim ~~21~~³, wherein said fusion protein is labeled with a detectable label.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,833,439 B1
DATED : December 21, 2004
INVENTOR(S) : Marcel Loetscher and Bernhard Moser

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 45

Line 23, delete "1" and insert --7--.


MAILING ADDRESS OF SENDER:

021005
Hamilton, Brook, Smith & Reynolds, P.C.
530 Virginia Road, P.O. Box 9133
Concord, Massachusetts 01742-9133

FORM PTO 1050 (Rev. 2-93)

PATENT NO. 6,833,439 B1

No. of add'l copies
@ 50¢ per page



JAN 31 2005

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,833,439 B1
DATED : December 21, 2004
INVENTOR(S) : Marcel Loetscher and Bernhard Moser

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 45

Line 23, delete "1" and insert --7--.

MAILING ADDRESS OF SENDER:

021005
Hamilton, Brook, Smith & Reynolds, P.C.
530 Virginia Road, P.O. Box 9133
Concord, Massachusetts 01742-9133

PATENT NO. 6,833,439 B1

No. of add'l copies
@ 50¢ per page

JAN 31 2005

➡ -0-